Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-001 in advanced HER3-positive solid tumours
ISRCTN62918594Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of hmbd-001 in bladder cancer, triple-negative breast cancer (TNBC), prostate cancer (PCa) and 11 more (3 arms), sponsored by Cancer Research UK. Primary endpoints: Number of patients who experienced dose-limiting toxicities in Part A, Number of patients who experienced dose-limiting toxicities in Part B Arm 1 and 3 more. Started Oct 2021; status: completed.
02
Drugs
hmbd-001
03
Conditions
bladder cancertriple-negative breast cancer (TNBC)prostate cancer (PCa)Cervical Cancer (CC)colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN62918594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62918594.